Oliver Hartley

Oliver Hartley

Company: Orion Biotechnology

Job title: Vice President, Drug discovery


Advancing the Optimization of Lead Biologic Candidates using New Screening Platforms 2:10 pm

What is the workflow to screening for highly specific biologics How to enhance binding affinity of anti-GPCR antibodies with chemical optimization? How to exploit the druggability of antibodies to target previously undrugged GPCRs?Read more

day: Day One Track B PM

Discovering the Next-Generation of GPCR-targeted Therapeutics to Address Metabolic Diseases with Unmet Patient Needs 10:00 am

Leveraging a novel drug modality and proprietary discovery platform to unlock peptide & protein GPCRs Advancing a pipeline of differentiated therapeutics for cardiometabolic and immunological diseases Capturing the untapped potential of Class A and Class B GPCRs with novel therapeutic approaches and drug-conjugates  Read more

day: Day Two AM

TRACK B: Hit ID & Optimization
10:35 am

Read more

day: Day One Track B AM

Chair’s Opening Remarks 8:50 am

Read more

day: Day One AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.